Related Experiment Video
Updated: Feb 4, 2026

Porcine As a Training Module for Head and Neck Microvascular Reconstruction
Published on: September 29, 2018
Driving progress in recurrent and metastatic head and neck cancer: the NRG Oncology perspective
Mercedes Herrera1, Matthew Ward2, Glenn J Hanna3
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Abstract:
Head and neck cancers represent a diverse group of malignancies with substantial heterogeneity in biology and prognosis for which management of advanced-stage disease remains a formidable challenge. Although the incorporation of immune checkpoint inhibitors has led the way to a new era of treatment possibilities, the current state of the science calls for further innovation and a nuanced approach to clinical trial design to address several unmet needs. This article from the NRG Oncology Recurrent/Metastatic Head and Neck Working Group aimed to critically identify gaps in clinical practice and the scientific literature and to propose actionable recommendations for future research in the framework of recurrent or metastatic squamous cell carcinoma of the head and neck.
Insights
Advanced head and neck cancers pose treatment challenges. This paper identifies research gaps and proposes strategies for recurrent/metastatic squamous cell carcinoma, aiming to improve patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trial Design
Background:
- Head and neck cancers are diverse with varied prognoses.
- Advanced-stage disease management remains challenging.
- Immune checkpoint inhibitors offer new treatment avenues.
Purpose of the Study:
- Identify clinical practice gaps in recurrent/metastatic head and neck cancer.
- Identify scientific literature gaps.
- Propose research recommendations for recurrent/metastatic squamous cell carcinoma of the head and neck.
Main Methods:
- Critical review of current clinical practice.
- Analysis of existing scientific literature.
- Expert consensus from the NRG Oncology Recurrent/Metastatic Head and Neck Working Group.
Main Results:
- Gaps in understanding tumor biology and treatment resistance identified.
- Need for novel clinical trial designs highlighted.
- Specific unmet needs in recurrent/metastatic squamous cell carcinoma outlined.
Conclusions:
- Further innovation is crucial for managing advanced head and neck cancers.
- A nuanced approach to clinical trial design is necessary.
- Actionable recommendations are provided for future research directions.
More Related Videos
Related Concept Videos
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Energy to Drive Translocation
Generally, polypeptides are unfolded by two distinct...
Muscles of the Anterior Neck

